Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Leases (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Capital Leases data on record, last reported at $643000.0 in Q4 2025.

  • For Q4 2025, Capital Leases fell 16.28% year-over-year to $643000.0; the TTM value through Dec 2025 reached $643000.0, down 16.28%, while the annual FY2025 figure was $643000.0, 16.28% down from the prior year.
  • Capital Leases reached $643000.0 in Q4 2025 per VRCA's latest filing, up from $629000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $2.0 million in Q3 2024 and bottomed at $13000.0 in Q2 2022.
  • Average Capital Leases over 5 years is $664600.0, with a median of $629000.0 recorded in 2025.
  • Peak YoY movement for Capital Leases: surged 2346.91% in 2024, then crashed 68.26% in 2025.
  • A 5-year view of Capital Leases shows it stood at $16000.0 in 2021, then dropped by 18.75% to $13000.0 in 2022, then skyrocketed by 7792.31% to $1.0 million in 2023, then decreased by 25.15% to $768000.0 in 2024, then fell by 16.28% to $643000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $643000.0 in Q4 2025, $629000.0 in Q3 2025, and $579000.0 in Q2 2025.